Analysts See $-0.13 EPS for Conatus Pharmaceuticals Inc. (CNAT)

October 14, 2018 - By Vivian Park

Investors sentiment decreased to 0.56 in 2018 Q2. Its down 0.55, from 1.11 in 2018Q1. It fall, as 23 investors sold Conatus Pharmaceuticals Inc. shares while 18 reduced holdings. 9 funds opened positions while 14 raised stakes. 9.33 million shares or 22.22% less from 11.99 million shares in 2018Q1 were reported.
Paloma Management holds 0.01% or 127,799 shares in its portfolio. Wells Fargo Company Mn holds 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 27,306 shares. Tci Wealth Advsr invested in 0% or 10 shares. Millennium Management Ltd Liability Corp accumulated 369,124 shares. Laurion Cap Mgmt Lp has invested 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Element Cap Llc stated it has 125,749 shares. Bridgeway Capital Mgmt reported 136,300 shares stake. Deutsche Bank Ag accumulated 0% or 10,347 shares. Gru One Trading Ltd Partnership holds 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 41,841 shares. 37,444 were reported by State Street Corporation. Bank Of Ny Mellon Corp has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Barclays Public Ltd Co accumulated 53,874 shares or 0% of the stock. Vanguard Gp reported 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Gsa Capital Prtnrs Limited Liability Partnership stated it has 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Mpm Asset Mngmt Ltd Liability owns 2.46M shares.

Analysts expect Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report $-0.13 EPS on November, 7.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.13 EPS. After having $-0.15 EPS previously, Conatus Pharmaceuticals Inc.’s analysts see -13.33 % EPS growth. The stock increased 3.54% or $0.17 during the last trading session, reaching $4.97. About 354,597 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has declined 18.52% since October 14, 2017 and is downtrending. It has underperformed by 34.14% the S&P500.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $149.95 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

More notable recent Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) news were published by: Globenewswire.com which released: “Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting” on October 02, 2018, also Seekingalpha.com with their article: “Expected Value Investing: Diving Deeper On Conatus” published on September 24, 2018, Globenewswire.com published: “Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences” on September 19, 2018. More interesting news about Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) were released by: Nasdaq.com and their article: “Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension” published on September 20, 2018 as well as Seekingalpha.com‘s news article titled: “Pfizer And Conatus: Emricasan And NASH” with publication date: September 19, 2018.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>